<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03949894</url>
  </required_header>
  <id_info>
    <org_study_id>156-402-00144</org_study_id>
    <nct_id>NCT03949894</nct_id>
  </id_info>
  <brief_title>Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease</brief_title>
  <acronym>ESSENTIAL</acronym>
  <official_title>Evaluating the Safety and effectivenesS in Adult KorEaN Patients Treated With Tolvaptan for Management of Autosomal domInAnt poLycystic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and therapeutic effectiveness of tolvaptan when administered to slow&#xD;
      the progression of cyst development and renal function insufficiency in adult Korean patients&#xD;
      diagnosed with rapidly progressive ADPKD who have chronic kidney disease (CKD) stages 1-3 at&#xD;
      initiation of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidences of TEAEs</measure>
    <time_frame>during the tolvaptan treatment period and up to 7 days after the date of last dosing</time_frame>
    <description>The incidences of TEAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The incidences of TEAEs meeting any of the followings will be summarized.</measure>
    <time_frame>during the tolvaptan treatment period and up to 7 days after the date of last dosing</time_frame>
    <description>Liver injury [ALT or AST elevation (&gt;3 x ULN) or Total Bilirubin elevation (&gt;2 x ULN), etc.], AEs leading to death, Serious AEs, AEs leading to treatment discontinuation, AEs whose causal relationship with the IMP cannot be ruled out, Severe AEs, Dehydration, Effects on Sodium, Creatinine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total kidney volume (TKV) annual mean percent change rate [%/year]</measure>
    <time_frame>from baseline to End of Treatment (Visit 25, Month 24)</time_frame>
    <description>Baseline TKV refers to the value measured during the screening period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR CKD-EPI annual mean change [mL/min/1.73m^2] (off-treatment)</measure>
    <time_frame>from baseline to the Follow-up visit (Visit 26, 7 days after End of Treatment(Visit 25, Month 24))</time_frame>
    <description>(off-treatment)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>eGFR CKD-EPI annual mean change [mL/min/1.73m^2] (on-treatment)</measure>
    <time_frame>from Completion of Tolvaptan Titration Period (Visit 6, Week 4) to End of Treatment (Visit 25, Month 24)</time_frame>
    <description>(on-treatment)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">118</enrollment>
  <condition>Autosomal Dominant Polycystic Kidney Disease (ADPKD)</condition>
  <arm_group>
    <arm_group_label>tolvaptan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tolvaptan</intervention_name>
    <description>30mg and 15mg of Tolvaptan Tablet</description>
    <arm_group_label>tolvaptan</arm_group_label>
    <other_name>Samsca</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects who voluntarily participate by giving written informed consent on this trial&#xD;
&#xD;
          2. Male and female patients aged ≥ 19 to ≤ 50 years&#xD;
&#xD;
          3. Subjects diagnosed with ADPKD based on the Unified Criteria for Ultrasonographic&#xD;
             diagnosis of ADPKD (Pei-Ravine Criteria)&#xD;
&#xD;
          4. Subjects with confirmed CKD stages 1-3 at the screening visit&#xD;
&#xD;
          5. Subjects with confirmed rapidly progressive typical ADPKD 'Typical ADPKD'&#xD;
&#xD;
               -  refers to bilateral and diffuse distribution, with mild, moderate or severe&#xD;
                  replacement of kidney tissue by cysts, where all cysts contribute similarly to&#xD;
                  TKV.&#xD;
&#xD;
        'rapidly progressive ADPKD'&#xD;
&#xD;
          -  Patients will be defined as 'rapidly progressive ADPKD' if they meet any of the&#xD;
             following criteria:&#xD;
&#xD;
               -  Mayo class 1C, 1D or 1E&#xD;
&#xD;
                    -  Truncating PKD1 mutation confirmed by genetic testing before participating&#xD;
                       this trial ③ PRO-PKD score &gt; 6 ④ Patients with ADPKD with a decline in&#xD;
                       Estimated glomerular filtration rate(eGFR) ≥ 5 mL/min/1.73 m2 within 1 year&#xD;
                       from the screening visit or with an average annual decline in eGFR ≥ 2.5&#xD;
                       mL/min/1.73 m2 over a period of 5 years (excluding patients with an eGFR&#xD;
                       decline due to factors other than ADPKD, such as uncontrolled type 2&#xD;
                       diabetes, early diabetic glomerular disease or immune-mediated&#xD;
                       glomerulonephritis)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with hyponatremia or hypernatremia&#xD;
&#xD;
          2. Patients with anuria&#xD;
&#xD;
          3. Patients with volume depletion&#xD;
&#xD;
          4. Patients who are unable to sense or appropriately respond to thirst&#xD;
&#xD;
          5. Patients with contraindications to MRI assessment [e.g., ferromagnetic metal&#xD;
             prosthesis, aneurysm clips, severe claustrophobia, large tattoo on the abdomen or&#xD;
             back, etc.]&#xD;
&#xD;
          6. Patients with severe renal impairment [e.g., patients with currently active&#xD;
             glomerulonephritis, kidney cancer, having a single kidney, history of renal surgery&#xD;
             within the last 3 years, etc.]&#xD;
&#xD;
          7. Patients with severe hepatic impairment [e.g., cirrhosis, viral hepatitis, unspecified&#xD;
             liver function test abnormalities (ALT or Aspartate aminotransferase(AST)) &gt; 3 x ULN&#xD;
             or Total Bilirubin &gt; 2 x ULN), etc.]&#xD;
&#xD;
          8. Patients with eGFR decline due to factors other than ADPKD (e.g., uncontrolled type 2&#xD;
             diabetes, early diabetic glomerular disease or immune-mediated glomerulonephritis,&#xD;
             etc.)&#xD;
&#xD;
          9. Patients with a history of hypersensitivity and/or specific reactions to benzazepine&#xD;
             or benzazepine derivatives (such as Benazepril), or tolvaptan&#xD;
&#xD;
         10. Patients with hereditary problems of galactose intolerance, the Lapp lactose&#xD;
             deficiency or glucose-galactose malabsorption, etc.&#xD;
&#xD;
         11. Patients who need chronic diuretic use&#xD;
&#xD;
         12. Patients who are receiving any experimental (not marketed) or approved therapies that&#xD;
             may affect the treatment of ADPKD within 6 months from the screening visit [e.g.,&#xD;
             anti-sense RNA therapy, rapamycin, sirolimus, everolimus and somatostatin analogs&#xD;
             (octreotide, sandostatin), vasopressin antagonist (mozavaptan, conivaptan),&#xD;
             vasopressin agonist (desmopressin)]&#xD;
&#xD;
         13. Patients who have received cyst decompression or sclerotherapy within 3 years from the&#xD;
             screening visit&#xD;
&#xD;
         14. Patients with a history of taking tolvaptan within 6 months from the screening visit&#xD;
&#xD;
         15. Patients who received any investigational medicinal product in another trial within 30&#xD;
             days from the screening visit&#xD;
&#xD;
         16. Fertile women who are currently pregnant or breat feeding, or not willing to use or&#xD;
             capable of using acceptable contraceptive methods (abstinence, oral, implanted or&#xD;
             injected hormonal methods of contraception, intrauterine device or barrier methods of&#xD;
             contraception, such as condom, contraceptive diaphragm and spermicidal agents) to&#xD;
             avoid pregnancy until completion of the trial&#xD;
&#xD;
         17. Patients who are, in the opinion of the investigator, unable to comply with the&#xD;
             administration of the Investigational Medicinal Product(IMP) or the trial procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Inje University Busan Paik Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kosin University Gospel Hospital</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Chuncheon Sacred Heart Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center</name>
      <address>
        <city>Pyeongchon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Kangnam Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hanyang University Seoul Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMG-SNU Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>May 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2019</study_first_posted>
  <last_update_submitted>September 14, 2020</last_update_submitted>
  <last_update_submitted_qc>September 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthrogryposis</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney, Autosomal Dominant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tolvaptan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

